Introduction
Cancer is a very dangerous disease and it is the second most common cause of death after heart disease in the world. 1 Numerous anticancer agents that can be used for cancer treatment have been developed, but most of them have high toxicity rates. 2 Therefore, the need to discover some new anticancer agents that are very efficacious in the treatment of cancer, but at the same time have very minimal toxicity rates, is one of the main objectives of organic and medicinal chemistry. 3 Pyrimidines attract great attention on account of their wide range of biological and pharmaceutical properties, such as anticancer, 4−7 antibacterial, 8, 9 antiinflammatory, 10−13 antiviral, 14 antituberculosis, 15, 16 antihypertensive, 17, 18 and anticonvulsant 19 properties. For this reason, the design and synthesis of pyrimidine derivatives as potential cancer agents have been extensively studied 20 and hundreds of pyrimidine derivatives have been synthesized and evaluated for their anticancer activity. 21−23 Moreover, various drugs containing a pyrimidine nucleus like 5-fluorouracil (5-FU), tegafur, and thioguanine were prepared and used as anticancer agents. 24, 25 Chalcones are known to show different biological activities, such as antioxidant, 26 antiinflammatory, 27 antimalarial, 28 antileishmanial, 29 anticancer, 30 and antitumor 31 activities.
Besides their biological activities, chalcones are very useful in starting materials for the preparation of bioactive heterocycles such as pyridine, pyrimidine, pyrazoline, and isoxazoline derivatives. As a follow-up to these results, we aim at the synthesis of novel 1,4-phenylene-bis-pyrimidine-2-amine derivatives from 1,4-phenylene-bis-chalcones, and we also investigate their anticancer activities against the C6 and HeLa cell lines.
Results and discussion

Chemistry
The synthetic approach to the desired compounds is given in the Scheme. The starting materials, 1,4-phenylenebis-chalcones (3a-3h), were prepared by Claisen-Schmidt condensation of terephthalaldehyde (2) and related arylketones (1a-h) in the presence of NaOH in EtOH (Scheme; Table 1 ). 1,4-Phenylene-bis-chalcones are known as 3a, 36 3b, 37 3c, 38 and 3e-3h.
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Scheme. The synthetic approach to the desired compounds.
Synthesized 1,4-phenylene-bis-chalcones were submitted to reaction with guanidine hydrochloride (4) to get 1,4-phenylene-bis-pyrimidine-2-amine derivatives. The 1,4-phenylene-bis-pyrimidine-2-amine derivatives (5a-5h) were synthesized by literature procedures. 40 Reaction of 1,4-phenylene-bis-chalcones (3a-3h) (1 equiv.) with guanidine hydrochloride (4) (8 equiv.) and KOH (2 equiv., 2.5 M) was started in dry ethanol under reflux conditions. After 2 h of reaction, the mixture was added to H 2 O 2 (35%, 20 equiv.) dropwise for 2 h. The mixture was then cooled to r.t. and transferred to HCl/ice. The precipitated solid products were filtered off, washed with methanol several times, and dried to yield the 1,4-phenylene-bis-pyrimidine-2-amine derivatives (5a-5h) (Scheme; Table 1 ).
The structures of 5a-5h were explained by spectral data (IR and NMR) and elemental analysis. All spectral data are in good agreement with the expected structures.
Anticancer activity results against C6 and HeLa cells
Anticancer activities against C6 and HeLa cells of 3a-3h and 5a-5h were investigated. The results were compared with 5-FU, which was used as a positive control.
The anticancer activities of 3a-3h were shown to increase dose-dependently against C6 cells ( Figure   1A ). Most of compounds 3a-3h exhibited significant activity compared to the 5-FU as the reference drug. Compounds 3c, 3d, and 3g showed almost the same activity as 5-FU, particularly at 75-100 µ M concentrations. While compounds 3a and 3e showed considerable activity, compounds 3b, 3f, and 3h exhibited moderate anticancer activities when compared to 5-FU. Inhibitory effects of the compounds on HeLa cells at 100 µ M revealed the following potency order: The anticancer activities of 5a-5h were also determined by the increase in dose-dependent activity against C6 cells ( Figure 1B ). The anticancer activity of 5h was better than that of 5-FU at high concentrations. Compound 5e exhibited a moderate anticancer effect, while compounds 5a-5d and 5f and 5g did not show any significant activity when compared to 5-FU. Inhibitory effects of the compounds on C6 cells at 100 µ M revealed the following potency order: 5h > 5-FU > 5e > 5c > 5b > 5f > 5g > 5a > 5d.
Anticancer activities of 3a-3h and 5a-5h were also determined against HeLa cells. The anticancer activities of 3a-3h and 5a-5h were shown to increase dose-dependently against HeLa cells (Figures 2A and   2B , respectively). The anticancer activity of compounds 3c and 3d was better than that of 5-FU at high concentrations (30-100 µ M). Moreover, the others (except 3h) showed moderate activity when compared to 5-FU. Inhibitory effects of the compounds against HeLa cells at 100 µ M revealed the following potency order: (Figure 2A ). The anticancer activities of compounds 5a-5h are given in Figure 2B . Compound 5h exhibited moderate activity, whereas the others did not show any significant activity when compared to 5-FU ( Figure 2B ). Inhibitory effects of the compounds on HeLa cells at 100 µ M revealed the following potency order: 5-FU > 5h > 5b > 5e > 5a > 5d > 5c > 5f > 5g.
When comparing 1,4-phenylene-bis-chalcones 3a-3h with 1,4-phenylene-bis-pyrimidines 5a-5h, it was seen that 1,4-phenylene-bis-chalcones 3a-3h were more effective against both cell lines (C6 and HeLa) than 1,4-phenylene-bis-pyrimidines 5a-5h.
Among all tested compounds, the most active compounds against both cell lines were compounds 3c and 3d, followed by compounds 3e and 3h against C6 and 5h against C6 (at 75-100 µ M concentrations), when compared with 5-FU. This result indicated that the thiophene and furan ring and the p -chloro substituent enhanced anticancer activity.
Additionally, IC 50 values were calculated by using ED50 Plus v1.0 and are given in Table 2 . Sample codes IC50 HeLa C6 3a 
General procedure for the synthesis of bis-pyrimidine derivatives (5a-5h)
A solution of bis-chalcone (3a-3h) (1 mmol), guanidine hydrochloride (4) (8 mmol), and KOH (2 mmol, 2.5 M) in ethanol was refluxed for 2 h. Continuing the reflux operation, to the reaction medium H 2 O 2 (20 mmol, 35%) was added dropwise within 2 h. After reflux, the reaction mixture was cooled to r.t. and the product was precipitated by the addition of dilute HCl. The precipitate was filtered and washed with methanol and dried. 
6,6'-(1,4-Phenylene)bis(4-(naphthalen-1-yl)pyrimidin-2-amine) (5a):
6,6'-(1,4-Phenylene)bis(4-(thiophen-2-yl)pyrimidin-2-amine) (5c):
Biological part
Preparation of stock solution
The compounds and 5-FU were solved by sterile dimethyl sulfoxide (DMSO) and were diluted with Dulbecco's modified Eagle's medium. The final concentration of DMSO was kept below 0.1% in all tests.
Cell culture and cell proliferation assay
The anticancer activity tests and cell culture studies were performed according to the literature. 41, 42 HeLa and C6 cells were used for the anticancer tests. The experiments were carried out at eight concentrations (5, 10, 20, 30, 40, 50, 75 , and 100 µ M).
Statistical analysis
The results are means ± SDs of nine values. Differences between groups were determined by the ANOVA method (P < 0.01). Statistical analysis was performed with SPSS 13.5.
Conclusion
A series of 1,4-phenylene-bis-chalcone derivatives (3a-3h) and new 1,4-phenylene-bis-pyrimidine derivatives (5a-5h) were designed, synthesized, and evaluated for their anticancer activity against the C6 (rat brain tumor)
and HeLa (human uterus carcinoma) cell lines. Among all the compounds that were tested, compounds 3c and 3d were found to be the most promising agents due to their significant antiproliferative effects against both cell lines. In addition, compounds 3e and 3h showed very high activity against C6. The pyrimidine series 5a-5h (except 5h) demonstrated very low activity against both cell lines, while compound 5h exhibited very high activity against C6 (at 75-100 µ M concentrations) when compared to 5-FU. These results are encouraging, but further studies are required to evaluate the mechanism of action for the anticancer activity of compounds 3c, 3d, 3e, 3h, and 5h.
